RSV vaccine delivery expands while next-generation candidates advance

WHO prequalification of a multidose Abrysvo presentation could improve the affordability, logistics, and reach of RSV prevention in lower-income countries, while Sabin and partners are promoting community and maternal-RSV delivery initiatives. Procurement, pricing, rollout timing, and uptake remain open; Clover’s Phase 2 candidates show encouraging antibody responses and short-term tolerability, yet clinical protection is unproven.